Boehringer Ingelheim, Eli Lilly announce improved cardio-renal outcomes in trial with jardiance
Jardiance reduced risk of cardiovascular death and hospitalisation for heart failure, along with serious adverse kidney outcomes in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Oct 20
Jardiance reduced risk of cardiovascular death and hospitalisation for heart failure, along with serious adverse kidney outcomes in…
12 Oct 20
Zeposia met both primary and secondary efficacy endpoints in the clinical trial and showed statistically significant improvements
08 Oct 20
The data from interim post-authorisation study showed an overall performance of 93.3% sensitivity and 98.4% specificity for ID…
08 Oct 20
Phase 3 AFFINE study is an open-label, multicentre, single-arm study, designed to evaluate the efficacy and safety of…
07 Oct 20
The phase 3 COMET-ICE trial will evaluate the safety and efficacy of a single intravenous infusion of VIR-7831…
25 Sep 20
The late-stage clinical trial is designed to enrol up to 10,000 volunteers across the UK to evaluate the…
24 Sep 20
Phase 3 ENSEMBLE study is designed to enrol up to 60,000 adult volunteers to evaluate the safety and…
14 Sep 20
The UK committee has resolved its investigations and recommended the MHRA that Covid-19 vaccine trials in the UK…
11 Sep 20
ENSPRYNG was recently approved by the US Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody…
09 Sep 20
The UK-based drugmaker has voluntarily paused the clinical trials to ensure the review of safety data by an…